Inositol for PMOS, previously called PCOS: useful for some, oversold for many
A clear-eyed look at what the inositol research actually shows - who benefits, who doesn't, and how to trial it without fooling yourself.
- 30 trials, 2,230 participants - the largest meta-analysis still concluded benefit is mixed.
- 40:1 ratio at 2-4g myo-inositol per day is the most studied protocol.
- Metformin has greater efficacy per the international guideline.
- Helps many, not all - we can't yet predict who will respond.
- Not first-line for fertility - letrozole is the guideline recommendation for anovulatory infertility.
What is inositol, and how is it supposed to work?
The short answer: Inositol is a sugar alcohol that exists naturally in your body. The two forms studied for PMOS - myo-inositol and D-chiro-inositol - act as messengers in insulin signaling. The theory is that improving how cells respond to insulin can ease some of the downstream effects of PMOS, including hormonal and metabolic ones.
Most clinical research uses a 40:1 ratio of myo-inositol to D-chiro-inositol. This ratio matches the natural balance maintained in ovarian follicles. Standard study doses range from 2 grams to 4 grams of myo-inositol per day, often combined with around 50 milligrams of D-chiro-inositol.
If you've seen this ingredient marketed as a "PCOS solution" on Instagram, that framing is louder than the evidence supports. The next sections explain what the actual data shows.
What does the evidence actually show?
The short answer: A 2023 systematic review and meta-analysis - commissioned to inform the international PMOS guideline - pooled 30 trials with 2,230 participants. It found inositol may help some metabolic measures, and D-chiro-inositol may benefit ovulation. For most other outcomes, including weight, hirsutism, and reproductive markers, the evidence was weaker or inconsistent.1
The guideline's own summary was clear: "Metformin is recommended primarily for metabolic features and has greater efficacy than inositol, which offers limited clinical benefits in PCOS."2
Source: Monash University systematic review, informing the 2023 International Evidence-Based PMOS Guideline.
The "limited clinical benefit" language is doing a lot of work in that summary. It does not mean "useless." It means that in the controlled trials reviewed, the average effect size for outcomes people care about - ovulation regularity, weight, visible hirsutism - was small or inconsistent. Some participants improved. Others didn't. The averages were modest.
Who might benefit?
The short answer: If your main goal is metabolic - fasting glucose, insulin sensitivity, lipid markers - and you want a low-side-effect intervention, inositol is a reasonable trial. If your main goal is something else (ovulation induction for fertility, hirsutism, significant weight change), there are evidence-stronger options to discuss with your clinician first.
The honest framing from the meta-analysis is that inositol "helps many, not all." That's not a marketing line. It's the data. Around half of trial participants showed measurable metabolic improvements. The other half didn't. We can't yet predict which group anyone will fall into.
Metformin is recommended primarily for metabolic features and has greater efficacy than inositol, which offers limited clinical benefits.
- 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS2
The guideline still permits inositol as an option, because for some people the lower side-effect profile compared to metformin is meaningful. But the comparative efficacy is honest, and it should change how you frame the decision.
What about dose and product quality?
The short answer: The guideline explicitly notes that "no specific form, dose, or combination of inositol can yet be recommended" because the evidence quality is still poor. Most well-designed studies used the 40:1 myo-to-D-chiro-inositol ratio at total doses of 2-4 grams per day. Beyond that, the field is open.
Product quality varies widely. Inositol is a supplement, not a medication, which means manufacturing standards and ingredient verification differ from product to product. If you're going to trial inositol, look for products that publish a Certificate of Analysis showing actual inositol content, third-party testing, and a clean ingredient list.
A trial done well is more honest than a year of guessing.
When inositol is not the right first move
The short answer: If your primary goal is infertility treatment, inositol is not the evidence-first place to start. Letrozole is the guideline-recommended first-line option for anovulatory infertility in PMOS when there are no other infertility factors. Metformin sits ahead of inositol for metabolic outcomes and hirsutism. Combined oral contraceptive pills are first-line for menstrual irregularity and androgen excess.2
Using inositol as an opening move when something stronger is indicated isn't gentle. It's just slower.
The bottom line
What we know: Inositol has some clinical-trial support for metabolic measures and (with D-chiro-inositol) for ovulation. The 2023 international guideline allows it as an option but says metformin has greater efficacy. Side effects are generally mild.
What we don't know yet: Why some people respond strongly and others don't. The optimal dose, ratio, and duration for different goals. Whether benefits last after stopping. Whether different PMOS phenotypes respond differently.
What to do next: Decide your priority outcome before starting. If it's metabolic and you want lower side effects than metformin, inositol is a reasonable trial done well - for 12 weeks, with measurement. If it's something else, ask your clinician about the evidence-stronger first option for that goal.
References
- Greff D et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Monash University. 2023. [Link]
- Teede HJ et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023. [Link]
- American Society for Reproductive Medicine. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. ASRM Practice Guidance. [Link]
- Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. DOI: 10.1016/S0140-6736(26)00717-8.